argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Citigroup Inc. from $681.00 to $796.00. They now have a "buy" rating on the stock.
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $715.00 price target on the stock.
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $720.00 price target on the stock.